Lucio C. Rovati

Etna Biotech (Italy) — Italy

Medicine · Health Sciences

51h-index10.4kcitations359works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Inflammatory mediators and NSAID effects(84), Osteoarthritis Treatment and Mechanisms(76), Neuropeptides and Animal Physiology(60), Colorectal Cancer Treatments and Studies(31), Rheumatoid Arthritis Research and Therapies(20)

Publications359 total

Structure, substrate recognition and therapeutic targeting of the human ADAMTS-5 spacer domain
Acta Crystallographica Section D Structural Biology·2025
Phase I/II study of the EP4 antagonist vorbipiprant combined with anti-PD-1 immunotherapy: Safety and efficacy results in metastatic gastrointestinal non-colorectal cancers.
Journal of Clinical Oncology·2025
CR10049, THE FIRST OA-TARGETED KINASE INHIBITOR, AS A TREATMENT FOR THE INFLAMMATORY OA PHENOTYPE
Osteoarthritis and Cartilage·2025
Figure 1 from The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial
2025Open Access
Supplementary Table S3 from The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial
2025Open Access
Supplementary Figure S3 from The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial
2025Open Access
Supplementary Figure S1 from The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial
2025Open Access
Figure 2 from The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial
2025Open Access
Supplementary Figure S5 from The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial
2025Open Access
Supplementary Table S1 from The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial
2025Open Access
Supplementary Figure S3 from The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial
2025Open Access
Supplementary Table S1 from The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial
2025Open Access
Data from The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial
2025Open Access
Supplementary Table S2 from The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial
2025Open Access
Table 3 from The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial
2025Open Access
Supplementary Methods S1 from The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial
2025Open Access
Supplementary Table S3 from The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial
2025Open Access
Table 1 from The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial
2025Open Access
Supplementary Table S4 from The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial
2025Open Access
Supplementary Table S2 from The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial
2025Open Access
page 1 of 18Next →

Frequent Co-authors

Giampaolo Giacovelli(13), I Setnikar(11), Olivier Bruyère(9), Yves Henrotin(5), Christoph Beglinger(5), Rita Deroisy(4), Karel Pavelká(4), C. B. H. W. Lamers(4), Stefano Persiani(4), Jean‐Yves Reginster(3), J Gatterová(3), Marta Olejarová(3), Marc C. Hochberg(3), Massimo D’Amato(3), Jan B.�M.�J. Jansen(3), Marcello Locatelli(3), Aldo Roda(3), Laurence Seidel(3), Gianfranco Caselli(3), Cyrus Cooper(2)